Register Now: Image-Based Risk: The Next Frontier in Breast Cancer Screening
|Articles|March 26, 2004

GE launches nuclear medicine platform

Other headlines:TomoTherapy enters Middle East

GE launches nuclear medicine platform

A new breed of gamma technology will soon join the GE Healthcare portfolio for nuclear cardiology. The company's newly released Alcyone platform combines cadmium zinc telluride (CZT) detectors, focused pin-hole collimation, 3D reconstruction, and stationary data acquisition to improve workflow, dose management, and overall image quality, according to the company. The technology platform, set to be unveiled March 29 at the American College of Cardiology meeting, will be available on both the Discovery NM 530c and the Discovery NM/CT 570c. Heightened sensitivity and zero equipment motion translate into improved image quality and energy resolution, potentially enabling new clinical applications. Among them are 3D dynamic acquisitions and simultaneous dual-isotope imaging. The new platform will cut scan times from 15 to 20 minutes to three to five minutes, according to GE. A shorter, more comfortable scan promises to improve image quality by reducing the likelihood of artifacts.

TomoTherapy enters Middle East

Saudi Arabia's leading cancer center, King Faisal Specialist Hospital and Research Centre in Riyadh, is the first in the Middle East to offer patients treatment with TomoTherapy's Hi•Art radiation therapy system. A ribbon-cutting ceremony held March 9 inaugurated the image-guided intensity-modulated radiation therapy system.


Related to this article

Emerging Research Insights and New Advances in Neuroradiology
Catch up on key neuroradiology news and research from the past month, including recently published studies involving white matter hyperintensity findings on brain MRI, MRI-enhanced amyloid PET and the newly FDA-approved PET agent floretyrosine F18 for glioma imaging.